Mammalian sialidase Neu4, ubiquitously expressed in human tissues is located in the lysosomal and mitochondrial lumen and has broad substrate specificity against sialylated glycoconjugates.
INTRODUCTION
Emerging evidence suggests that polysialylated and monosialylated glycolipids (gangliosides) play important roles in embryogenesis, development, immune response, signal transduction and cell death (reviewed in 11, 18, 35, 41) . Catabolism of gangliosides involves a step-wise desialylation catalyzed by mammalian neuraminidases (or sialidases). These hydrolases are encoded by the Neu1, Neu2, Neu3 and Neu4 genes the products of which vary in subcellular location, tissue distribution, expression level and specificity. Neu1 is a component of the lysosomal multienzyme complex along with β-galactosidase (GAL) and the lysosomal carboxypeptidase, cathepsin A (CathA), which stabilizes the catalytically active conformation of Neu1 and protects it against rapid proteolytic degradation in the lysosome (reviewed in 31).
Inherited deficiency of Neu1 causes the severe multisystemic neurodegenerative disorder, sialidosis. A clinically similar disorder, galactosialidosis, is caused by secondary Neu1 deficiency due to genetic defects in CathA. In both disorders, patients present with coarse facies, hepatosplenomegaly, dysostosis multiplex, bilateral macular cherry-red spots, mental and motor retardation (reviewed in 5, 42) and show tissue storage and urinary excretion of sialyloligosaccharides and sialoglycopeptides.
Neu2 is a cytosolic protein found mostly in skeletal muscles and is active against α2-3-sialylated oligosaccharides, glycopeptides and gangliosides (26, 27, 43) . The exact biological role of this enzyme is not known, but it was suggested to cleave G M3 ganglioside, associated with the cytoskeleton, leading to the alteration of cytoskeletal functions (1, 9, 34) . Neu3 is a ubiquitously expressed integral membrane protein localized in caveolae microdomains of plasma membranes 4 (28, 45, 46) . Its highest expression is found in adrenal gland, skeletal muscles, heart, testis and thymus (28, 45) . The enzyme is active mostly against gangliosides, including G M1 and G D1a (37) . Neu3 is probably involved in the modulation of the oligosaccharide chains of gangliosides on the cell surface in the course of transformation, differentiation and formation of cell contacts (20, 21) . In particular, it is implicated in cell signalling during neuritogenesis (48) , carcinogenesis and apoptosis (17) , as well as in insulin signalling (33) .
The physiological role of the recently identified sialidase Neu4, an enzyme ubiquitously expressed in human tissues is not clear. We showed that Neu4 is located in the lysosomal lumen and that it has a broad substrate specificity against glycoproteins, oligosaccharides, and sialylated glycolipids. This raised the question of a potential overlap of biological functions between Neu4 and Neu1 (38) . In contrast, others have shown that the majority of Neu4 is targeted to the inner and outer mitochondrial membranes and proposed that this enzyme may be involved in the cleavage of G D3 ganglioside in the mitochondria of apoptotic cells (49) . Here we report that cultured HeLa cells stably transfected with Neu4 siRNA, as well as mice with targeted disruption of the Neu4 gene, show partially impaired catabolism and lysosomal storage of gangliosides suggesting that Neu4 is a critical functional component of the ganglioside metabolizing system.
RESULTS

Neu4 catalyzes the conversion of gangliosides and compensates for β-hexosaminidase A deficiency.
Previously, we and others have shown that in the presence of detergents, Triton X-100 or sodium cholate, Neu4 is highly active against a broad range of ganglioside substrates (38, 49 ). Here we demonstrate that Neu4-transfected cells show sialidase activity against G D1a , G M3 The activity of Neu4 against gangliosides was further studied using immortalized neuroglia cells from a Tay-Sachs patient that accumulates G M2 ganglioside in culture due to the genetic deficiency of lysosomal β-hexosaminidase A (15) . Immortalized neuroglia cells derived from normal controls and from the Tay-Sachs patient as well as Tay-Sachs cells transfected with the Neu4-expressing plasmid (38) Figure 1B) , while, as before, the Tay Electron microscopy revealed that these cells had large heterogeneous lysosomes containing lamellar structures indicating lysosomal storage due to the suppressed Neu4 expression ( Figure   2C ). The lysosomal storage was also observed in immortalized normal human neuroglia cells 
Brain expression of Neu4 and behavioural analysis of Neu4-deficient animals. Previous
Northern blot analysis showed that in mouse Neu4 is expressed in the brain at a higher level than in other tissues (4) . To address the distribution of Neu4 mRNA in the brain, we analysed coronal To determine if the altered ganglioside pattern in the brain of the Neu4 -/-mice was sufficient to result in behavioural deficits reflective of the loss of neurons and progressive neurodegeneration similar to that detected in other sphingolipidoses, we performed a behavioural examination of 2-month-old and 10-month-old siblings of both genotypes. Open field, water maze and rotarod tests were conducted. These are tests that have previously been effective in monitoring the progression of the disease in the mouse model of Tay-Sachs disease (25) . While the outcomes were variable, Neu4 -/-mice at both 2 and 10 months showed no deficits in any of these tests (Supplementary Fig 6) . However, more in depth studies will be required to rule out subtle defects.
DISCUSSION
While Neu4 has been characterized in mouse and human tissues, the reports on subcellular localization and potential specific function of this enzyme have varied. The pH optimum of human and mouse Neu4 is extremely acidic, reported in the range of 3.2 to 4.8, as expected of a lysosomal hydrolase, although it has a minor neutral peak as well (29, 38, 49) Niemann-Pick disease (3, 12, 44) .
In the lungs and spleen of young (4 weeks to 4 months) animals, the elevated level of gangliosides and other lipids was accompanied by lysosomal storage, mostly affecting tissue macrophages. Lysosomal storage was also observed ex vivo when the splenocyte-derived macrophages from the Neu4 -/-mice were loaded with total gangliosides. On the other hand, in contrast to many lysosomal enzymopathies, the lysosomal storage and vacuolization in the tissues of the Neu4 -/-mice did not progress with age. Moreover, the microscopic examination of lungs and spleen from older (6-10 months of age) Neu4 -/-mice showed generally a normal morphology, suggesting that expression of the Neu4 gene is particularly important during postnatal development.
In the lungs, the lamellar bodies in the type II pneumocytes of the Neu4 -/-animals remained 2
fold enlarged even at 8 months of age. These organelles, which typically present concentric or parallel lamellae, are secretory granules containing phospholipids, glycosaminoglycans and surfactant proteins, synthesized by the type II pneumocytes. They are continuously formed and for the α-subunit of lysosomal β-hexosaminidase A. This enzyme converts G M2 to G M3
ganglioside. Hexa -/-mice, depleted of β-hexosaminidase A, remain asymptomatic to at least 1 year of age (25), owing to the ability of these mice to catabolize stored G M2 ganglioside via a lysosomal sialidase into glycolipid G A2 . G A2 is further processed by β-hexosaminidase B, to yield lactosylceramide (32), thereby completely bypassing the β-hexosaminidase A defect (Figure 7 ).
This bypass is not effective in humans, with the outcome that infantile Tay expression in human tissues was more widely distributed, with brain levels lower than in other tissues (29, 38, 49) . Strikingly, we show that transfection of human Tay-Sachs neuroglia cells with Neu4 produces a similar catabolism through G A2 , effectively "treating" the disease through the same metabolic bypass that is so effective in the mouse model. It is attractive to speculate that stimulation of human Neu4, perhaps through drug-mediated induction or activation, could activate the bypass in human Tay-Sachs disease or could substitute for Neu1 in human sialidosis and galactosialidosis and provide treatments of these devastating diseases. (NFR) as shown in Figure 3A . ES clones were further screened by Southern blot hybridization with genomic 5'-probe that were outside of the targeting construct ( Figure 3A ). Targeted ES clones were then injected into C57BL/6H blastocysts and implanted into pseudo-pregnant females. The resulting male chimeras were crossed with C57BL/6J and offspring that received the ES genome was identified by the inheritance of the agouti coat color and genotyped by Southern Blot hybridization using the 5'flanking probe as described in Figure 3B . Multiplex PCR primers 5'-CTC TTC TTC ATT GCC GTG CT-3' (N4e3F) 5-GCC GAA TAT CAT GGT GGA AA-3' (N4NeoF) and 5'-GAC AAG GAG AGC CTC TGG TG-3' (N4i3R) were used to genotype mice in the F2 generation.
MATERIALS and METHODS
Animals
To document the absence of Neu4 gene expression, Northern analysis was performed using 25 μg of total RNA extracted from the total frozen brain tissues of Neu4 -/-and wild type mice using the Trizol Fractionation of brain tissues. Brains from 6-month-old wild type and Neu4 -/-mice were rapidly dissected, frozen in liquid nitrogen, homogenized in 1 ml of lysis buffer (5 mM MOPS pH 7.4, 250 mM sucrose, 1 mM EDTA, 0.1% Ethanol) and separated by centrifugation to the nuclear fraction and post-nuclear supernatant as described (22) . Heavy organellar, light organellar and microsomal fractions were obtained by consequent centrifugation of post-nuclear supernatant at 5,500 g for 10 min, 18,000 g for 30 min and 105,000 g for 1 hr.
Enzyme assays. Sialidase, β-glucosidase and β-hexosaminidase activities in cellular homogenates and in subcellular fractions from brain tissues of Neu4 -/-and wild type littermates mice were assayed using the corresponding fluorogenic 4-methylumbelliferyl glycoside substrates as previously described (38) . Glutamate dehydrogenase (mitochondrial marker enzyme) activity in subcellular fractions from brain tissue was measured as described elsewhere (36) . Sialidase activity against G M1 , G M2 , and G D1a gangliosides and against total porcine brain gangliosides (all Avanti Polar Lipids) was measured as described (37) . The concentration of released sialic acid was measured by the thiobarbituric method (23) . Protein concentration was determined according to Bradford (2) . 
